Cover Story
FreeGuest Editorial
When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.This is a formidable challenge. Cancer trials were, and remain, notoriously time-consuming to launch, expensive to run, and difficult to enroll patients to. A deeper understanding of cancer biology and the genomics revolution in medicine have changed how we approach clinical research.When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Radiation oncologist, global health expert C. Norman Coleman dies of sarcoma at 79
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC
Pooled analysis finds correlations between early endpoints and OS in ICI trials - CMS starts paying for patient navigation; ACS offers navigation credentialing program
- Population scientist Monica Baskin is the “Jackie Robinson” of cancer center deputy directors
- Lillian Siu named 2024-2025 president-elect of AACR